NEWS

· November, 2016
VCN Biosciences to present clinical data on systemic administration of VCN-01 in pancreatic cancer patients at 28th EORTC-NCI-AACR SYMPOSIUM on Molecular Targets & Cancer Therapeutics.
> Read PDF

· February, 2016
VCN Biosciences initiates Part II of its on-going Phase 1 clinical trial with VCN-01 in pancreatic cancer patients.
> Read PDF

· February, 2016
VCN Biosciences announces that MINECO has granted funding for the project Cure4RB to clinically develop its lead candidate VCN-01 for the treatment of retinoblastoma.
> Read PDF

· May, 2014
VCN Biosciences announces initiation of clinical studies of VCN-01 in cancer patient.
> Read PDF

· July, 2013
VCN Biosciences' new facilities at Grifols Corporate Offices.
> Read PDF

· July, 2013
VCN Biosciences presents its results on chemosensitizing capabilities of VCN-01 in the Seventh International Meeting On Replicating Oncolytic Virus Therapeutics, held in Quebec (Canada).
> Read PDF

· July, 2013
VCN Biosciences has secured intellectual property rights in Spain for the hyaluronidase technology included in its lead candidate VCN-01. The Spanish Office for Patents and Trademarks (OEMPS) granted a patent (ES23852251 B1) entitled "Adenovirus oncolíticos para el tratamiento del cancer". The claims cover oncolytic adenoviruses expressing hyaluronidase enzyme to enhance its antitumoral efficacy.
> Read PDF

· October, 2012
VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles.
> Read PDF

· July, 2012
Grifols group enters VCN Biosciences aquiring equity shares and warrants the development of therapeutic candidates of the company.
> Read PDF

· Jun, 2012
VCN Biosciences is again present at the BIO International Convention in Boston , the largest global event in biotech sector around the world.
> Read PDF

· May, 2012
VCN Biosciences exposes to European Medicines Agency and Spanish Medicines Authority its development for VCN-01.
> Read PDF

· October, 2011
VCN Biosciences has signed a Cartera Tecnológica contract with Genoma España for the development of its product portfolio.
> Read PDF

· June 22th, 2011
VCN Biosciences is present at 2011 edition of the BIO International Convention.
> Read PDF

· June 15th, 2011
VCN Biosciences obtains Orphan Drug Designation from European Medicines Agency (EMA) to their candidate VCN-01 in the treatment of human exocrine pancreatic tumors.
> Read PDF

· January 18th, 2011
VCN Biosciences appears in the January 2011 issue of the supplement “+Innovació” on new business ideas from El Pediódico.
> Read PDF

· December 2010
VCN Biosciences wins the BioEmprenedor XXI award, a prize that recognizes the best Business Plan for innovative companies in Life Sciences sector.
http://forum.biocat.cat/index.asp?Idioma=CA&opc=17&pag=Premis_Bioemprenedor.

· November 15th, 2010
Biocentury (the Bernstein Report on BioBusiness) publishes in its issue form Novembre 15th, 2010 a report on VCN in its “Emerging Company profile” section: “VCN anti-tumor Ad-vantages” .
> Read PDF

· October 23th, 2010
VCN is invited to present data on VCN-01 at the Congreso Oncológico Ciudad de Benavente (Zamora)
> Read PDF

· August 30th, 2010
VCN obtains exclusive license on hyaluronidase technology from IDIBELL


· February 17th, 2010
VCN creation generates interest in economic media.
> Read PDF

· July 2nd, 2010
VCN sub-license T1 technology to ORCA Therapeutics .

“ORCA Therapeutics B.V. a biopharmaceutical company in the field of virotherapy, today announced that it obtained an exclusive license from VCN Biosciences L.S. in Gelida (Barcelona), Spain, to their T1 oncolytic adenovirus technology for the treatment of cancer. This license allows ORCA Therapeutics to develop and commercialize new next generation oncolytic adenoviruses with increased oncolytic potency.
“We are very excited to have in licensed this technology from VCN Biosciences. Securing this intellectual property will enhance our competitive position in virotherapy” said Dr. Janneke Meulenberg, CEO of ORCA Therapeutics B.V. This license from VCN Biosciences offers us a unique opportunity to combine our oncolytic adenovirus technology and know-how with the T1 technology to develop more effective oncolytic adenoviruses for treatment of cancer”
“We have been looking for a company whose intellectual property could be combined with the T1 technology to move it towards clinical application. ORCA is the ideal partner. A preceding scientific collaboration between founder scientist of ORCA and us has led to present agreement that prioritizes clinical translation and gives both partners a good opportunity to grow”, said Dr. Manel Cascallo, COO of VCN Biosciences.



Biosciences